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EDITORIAL
Fosfomycin: what was old is new again
Introduction
With the rising prevalence of antibiotic resistance in
bacteria, there is a need to develop new antibiotics and
re-visit older antibiotics where there are no available
alternatives. Fosfomycin, ﬁrst discovered in the 1960s,1
has a long history of use in some countries (including
the United States, Japan and several European coun-
tries), particularly for urinary tract infections.2 In
Australia, oral fosfomycin trometamol, previously only
available through the Special Access Scheme, has
recently been approved by the Therapeutic Goods
Administration for the management of acute, uncompli-
cated urinary tract infections in females over 12 years of
age, caused by Enterobacteriaceae (including Escherichia
coli) and Enterococcus faecalis, where the standard recom-
mended agents are not effective. Currently, it is not
subsidised by the Pharmaceutical Beneﬁts Scheme.
Mechanism of action and antimicrobial
activity and resistance
Fosfomycin is a bactericidal antibiotic agent. It inhibits
UDP-GlcNAc enolpyruvyl transferase, the ﬁrst step of
the synthesis of the bacterial cell wall.3 This unique
mechanism of action makes cross-resistance unlikely
and allows fosfomycin to retain signiﬁcant in vitro activ-
ity against many Gram-positive and Gram-negative
pathogens, including multidrug-resistant (MDR)
strains.4
Fosfomycin is primarily active against Gram-negative
urinary pathogens (Table 1).5 It has poor activity against
Pseudomonas aeruginosa and Acinetobacter spp.6 Fosfomycin
is active against both susceptible and multi-resistant
strains of E. coli and Klebsiella spp., including strains pro-
ducing extended spectrum beta-lactamases (ESBL). In
general, fosfomycin is more active against E. coli than Kleb-
siella spp. producing ESBL.7 The drug also retains activity
against some carbapenem-resistant Enterobacteriaceae.5
Obtaining fosfomycin susceptibility testing results in a
clinically relevant time frame can be a challenge for cli-
nicians in Australia. It is also important to consider some
technical concerns when interpreting susceptibility test-
ing results. The two most commonly used testing stan-
dards in Australia, the Clinical and Laboratory Standards
Institute (CLSI) and the European Committee on
Antimicrobial Susceptibility Testing (EUCAST), offer
simpliﬁed methods, which can be completed by most
laboratories. The CLSI, but not EUCAST, offer disk zone
diameter breakpoints for E. faecalis urinary isolates only8
Both EUCAST and CLSI provide disk zone diameter
breakpoints only for E. coli but recommend using a mini-
mum inhibitory concentration (MIC) method of testing
for other Enterobacteriaceae. It should be noted that the
breakpoints for oral fosfomycin have been calibrated
only for the treatment of uncomplicated urinary tract
infections and are not applicable to more complex dis-
eases (e.g. bacteraemia). Furthermore, the only reliable
method for testing the MIC of fosfomycin is agar dilu-
tion, with the addition of glucose-6-phosphate,9,10 which
is rarely available in clinical laboratories. Fosfomycin
susceptibility testing may therefore require referral to a
reference laboratory, further delaying results, as fosfo-
mycin is not typically included in ‘ﬁrst-line’ testing and
may only be completed once other resistance is detected
or on request by the clinician.
Resistance mechanisms for fosfomycin are usually chro-
mosomally encoded.6 High mutational frequency in vitro
does not often result in resistance or treatment failure in
vivo, probably due to the reduced ﬁtness of the strains asso-
ciated with mutation, particularly in E. coli. This could
explain why the resistance rates for fosfomycin against
common urinary pathogens, such as E. coli, Citrobacter spe-
cies and Proteus mirabilis, are low (i.e. <10%) even in
countries where the antibiotic is commonly used.5 There
have been case reports of failure of Klebsiella pneumoniae
carbapenemase (KPC)-producing K. pneumonia when fos-
fomycin is used as an adjunct therapy due to rapid selec-
tion of resistant variants.11 Although plasmid-mediated
resistance is rare, fosfomycin-modifying enzymes may also
be encoded on transferable plasmids, especially in E. coli.
This was initially reported in Japan and was subsequently
shown to be more pervasive in East Asia and China.12,13
Widespread penetration of these highly mobile plasmids,
and the fosfomycin resistance genes they carry, has the
potential to limit the efﬁcacy of fosfomycin in the future.
While it is likely that fosfomycin resistance rates in
Australia are currently low, we lack systematic microbio-
logical surveys to evaluate this. Plasmid-mediated resis-
tance appears to be increasing in neighbouring regions,
and additional studies are required to understand the local
resistance proﬁle.
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Paediatrics
Fosfomycin has not been systematically studied in chil-
dren and neonates, but numerous reports have docu-
mented success for various indications.14–18 Signiﬁcant
adverse effects have not been reported in this popula-
tion despite prolonged courses in some cases.14,19,20
Dosing regimens used in children vary considerably.
Oral doses of 100–200 mg/kg/day (3–4 divided doses)
have been used, with good effect and without evidence
of toxicity.18
Pregnancy
The pharmacokinetics of fosfomycin is unchanged by
pregnancy.21 Fosfomycin has been shown to be effective
in the treatment of cystitis and asymptomatic bacteriuria
in pregnancy, and adverse events are uncommon.22 It
has been shown to cross the placenta. Although available
data are limited, fosfomycin has not been associated with
teratogenicity (Category B2). There are no reliable data
on the use of fosfomycin during lactation.23
Renal failure
Fosfomycin does not undergo hepatic metabolism and
is primarily eliminated as an unchanged drug by the
kidneys through glomerular ﬁltration. About 38% of
the administered dose is eliminated in the kidneys.23
Limited information is available regarding dosage
adjustment in renal failure. The half-life of fosfomycin
increases and urinary excretion decreases as renal func-
tion decreases.24
Pharmacokinetics and toxicity
After a 3-g oral dose administered to healthy female vol-
unteers with normal renal function, large variability in
urinary concentrations was reported. Concentrations
remained above the EUCAST breakpoint of 32 mg/L in
100% of the volunteers over the ﬁrst 24 h, 67.5% for
48 h and 30% for 72 h. This high variability observed in
the pharmacokinetics of fosfomycin can potentially lead
to inadequate drug exposure and a lack of clinical
response.25 In general, fosfomycin has a good distribu-
tion into tissues, achieving clinically relevant concentra-
tions in serum, kidneys, bladder wall and the
prostate.5,24,26 Fosfomycin has also demonstrated antimi-
crobially effective concentrations in the infected lung tis-
sue of septic patients.27
The toxicity and adverse events associated with fosfo-
mycin have not been investigated as rigorously as for
newer agents; however, most reports suggest a favour-
able safety proﬁle.5 The most common adverse effects
are gastrointestinal, with symptoms, such as diarrhoea
and nausea, being reported with oral preparation in
2–8% of patients.28 The adverse effects have mainly
been evaluated following a single oral dose, and higher
rates of gastrointestinal side effects may be seen with
longer treatment courses.
Clinical use
Urinary tract infections are the most common infections
worldwide, and members of the family Enterobacteria-
ceae are the main pathogens responsible. With the
increase in antibiotic resistance, there are limited treat-
ment options, particularly for oral agents. Fosfomycin
has been evaluated for the treatment of these infections
when ﬁrst-line agents are no longer an option.29
Uncomplicated urinary tract infections (cystitis)
Most of the studies relating to fosfomycin efﬁcacy have
focused on uncomplicated urinary tract infection (cystitis)
in adult females. Several comparative studies in patients
with cystitis, using ﬂuoroquinolones, trimethoprim–sul-
phamethoxazole, nitrofurantoin, amoxicillin-clavulanate
and oral cephalosporins for 5–7 days compared to single
dose oral fosfomycin, have shown similar clinical and
microbiologic cure rates of between 75% and 95%.2,30,31
Most of these studies have been performed with less strin-
gent criteria and end-points than would be typically used
today. It should also be noted that some of the antibiotics
in the comparator arm of these studies are not recom-
mended as ﬁrst-line therapy for the management of
uncomplicated urinary tract infections in Australia. In
addition, the duration of therapy is longer than the
recommended guidelines.32
In a recently published randomised study by Huttner
et al., nitrofurantoin administered 100 mg three times a
day for 5 days was compared to a single 3-g dose of oral
Table 1 Spectrum of fosfomycin activity
ytilibitpecsuSmsinagrO
Gram positive Staphylococcus spp.
Enterococcus faecalis
Enterococcus faecium
Gram negative Escherichia coli
Klebsiella spp.
Acinetobacter spp.
Pseudomonas aeruginosa
Citrobacter species
Proteus spp.
Providencia spp.
Bacteroides fragilis
Highly susceptible ( ). Moderately susceptible ( ). Poor activity ( ).
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fosfomycin in women with uncomplicated cystitis. The
authors reported clinical resolution of 70% in those
patients receiving nitrofurantoin compared to 58% for
the fosfomycin group.33 Although the ﬁndings of this
study suggest that nitrofurantoin may have better clini-
cal effectiveness compared to a single dose of fosfomycin,
whether or not a multiple dose regimen of fosfomycin
would have been more effective is not clear.34
Pyelonephritis and prostatitis
Fosfomycin is primarily recommended (and registered)
for use in females with uncomplicated cystitis. However,
in patients with other types of urinary tract infection
caused by multidrug-resistant bacteria, it may be the
only potential oral option for therapy. There are limited
data available for the ‘Off Label’ use of fosfomycin. Man-
agement of these patients should be decided on an indi-
vidual basis, weighing the potential advantages versus
the risk posed by the lack of evidence related to both
safety for longer durations of therapy as well as efﬁcacy.
In addition, treatment of these patients is complex, and
the treatment of these patients should be done in consul-
tation with an expert in infectious diseases and/or clini-
cal microbiology.
Falagas et al., in a systematic review of observational
studies, reported that oral treatment with fosfomycin
was clinically effective against cystitis and pyelonephritis
caused by ESBL-producing E. coli.35 However, the evalu-
ation of patients in the subgroup with pyelonephritis
was only based on limited patient numbers, and no ran-
domised trials were included. For pyelonephritis, the
administration of multiple doses of oral fosfomycin
seems appropriate, but this is based on limited pharma-
cokinetic data, and the timing of the dosing intervals has
not been deﬁned. Even though it may be the only oral
option in some cases, there are insufﬁcient data to rec-
ommend fosfomycin for pyelonephritis or more severe
manifestations, such as bacteraemia. In addition, clini-
cians should be aware of the higher likelihood of clinical
failure with fosfomycin, and a higher risk of resistance
developing, when treating urinary tract infections caused
by Gram-negative bacteria other than E. coli.36
Fosfomycin can be considered an alternative for the
treatment of prostatitis because of its high oral bioavail-
ability and ability to attain concentrations in prostatic tis-
sue.26 There have been case reports of patients with
failure of ﬁrst-line therapy for acute prostatitis caused by
ESBL-producing E. coli who were subsequently cured
with a prolonged course of 3 g once-daily oral fosfomy-
cin.37 A retrospective case series evaluated patients who
failed ﬁrst-line treatment for chronic bacterial prostatitis,
including patients with MDR Enterobacteriaceae. The
patients received 3 g oral fosfomycin every 48–72 h for
6 weeks. After a median follow up of 20 months, seven
patients (47%) had a clinical response.38 Fosfomycin
may also prove to be a useful alternative in the preven-
tion of trans-rectal ultrasound-guided prostate biopsy-
related infectious complications in patients with a high
risk of quinolone resistance.39
Infections outside of the urinary tract
The in vitro activity of fosfomycin against MDR Gram-
negative organisms raises the hope that the drug may be
used as oral therapy of infections outside of the urinary
tract. From a clinical perspective, there is a small number
of case reports in which orally administered fosfomycin
has been used as follow-on therapy to intravenous anti-
biotics for signiﬁcant extra-urinary infections.40 However,
it is not recommended except in exceptional circum-
stances, under very close monitoring. Based on the maxi-
mum concentrations reported for oral doses of
fosfomycin, it would appear unlikely that oral fosfomycin
alone would prove useful for most non-urinary infec-
tions.41 In these patients, intravenous fosfomycin may be
considered. Intravenous fosfomycin has been adminis-
tered in critically ill patients with sepsis or nosocomial-
acquired infections due to methicillin-resistant Staphylo-
coccus aureus, vancomycin-resistant Enterococcus and MDR
Gram-negative bacteria, especially carbapenem-resistant
K. pneumoniae, in combination with other antibiotics.42
The effectiveness of intravenous fosfomycin has been
evaluated in many studies, which is beyond the scope of
this paper.43,44 The intravenous formulation in Australia
can only be accessed as an unapproved medication utilis-
ing the following mechanisms:
• The Special Access Scheme in Australia allows prescrip-
tion of an unapproved drug to a named patient where
there are no currently available treatment options.
There are provisions to supply drugs urgently for life-
threatening infections (Category A applications).
• An ‘authorised prescriber’ status can be designated for
expert physicians to prescribe unapproved antimicro-
bials where indicated. Although approval is not required
for each patient individually, reports must be provided
every 6 months on the number of patients treated.
How should oral fosfomycin be used
in Australia?
Most of the evidence for oral fosfomycin relates to its use
in uncomplicated urinary tract infections, for which this
agent has a long history of use in other countries. The
availability of another therapeutic option in the era of
increasing antimicrobial resistance is welcome. It is
recognised that older generic antibiotics, such as
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fosfomycin, are rarely commercially viable. However,
while it would seem an attractive option as a single-dose
treatment, the available evidence suggests that it may
not be as effective as other agents for uncomplicated uri-
nary tract infections. Therefore, its use should be
reserved for patients in whom there is resistance to other
ﬁrst-line antibiotics or where other agents are not toler-
ated. Although evidence for the use of fosfomycin for
more complicated infections is limited, its use can be
considered where resistance limits the use of other
options, particularly in ESBL-or carbapenemase-
producing organisms.
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